Abbvie Inc.

Abbott Laboratories Corporation

Other

Abbott Gmbh & Co Kg

Kevin Patrick Cusack

Thomas D Gordon

Adrian Hobson

Michael M Friedman

Michael Z Hoemann

Maria A Argiriadi

Eric C Breinlinger

Anna M Ericsson

Kristine E Frank

Kelly Mullen

Andrew Burchat

David Ihle

Graham K Ansell

Martin E Hayes

Shannon R Fix-Stenzel

Pintipa Grongsaard

Gloria Y Lo Schiavo

Lee Daniel Arnold

Michael E Kort

Kevin R Woller

Richard W Dixon

David J Calderwood

Martine Barth

Michael Morytko

Neil Wishart

Noel S Wilson

Biqin C Li

David Wayne Borhani

Lu Wang

Augustine Osuma

Robert V Talanian

Xiangdong Xu

Grier A Wallace

Xiaoyun Wu

Lei Wang

Gagandeep K Somal

James Patrick Stambuli

Jerome Amaudrut

Claude E Barberis

David Andrew Kinsman

Barbara F Scott

J Martin Herold

Bin Li

Philip Cox

Dominique Potin

Raymond Huntley

Lily K Abbott

Jérôme Amaudrut

Steve St Gallay

Euan Fordyce

Sami Osman

Hannah Dexter

Ciaran O'Reilly

Olivia Poupardin

Laurent Mounier

Robert H Stoffel

Xiaolei Zhang

Wouter Iwema Bakker

Kelly D Mullen

David W Borhani

Lu X Wang

Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, useful as RIPK1 inhibitors, and pharmaceutical compositions comprising same. Further provided are methods of use and preparation. Also provided are methods of treating Ulcerative Colitis using a compound of Formula (I).

Nicotinamide RIPK1 inhibitors

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions. 

Heterocyclic kinase inhibitors

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

Nuclear receptor modulators

The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Heterocyclic nuclear hormone receptor modulators

The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the individual receptors of the S1P receptor family.

Sphingosine-1-phosphate receptor agonist and antagonist compounds

Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

Indazole compounds

Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.

Oxadiazole compounds

The present invention is directed to a compound of formula (I), racemic-diastereomeric mixtures thereof, optical isomers thereof, prodrugs thereof, isotopes thereof or pharmaceutically-acceptable salts of said compound, isomers, prodrugs and isotopes, wherein the variables are defined herein. The compounds of this invention are useful as inhibitors of serine/threonine and tyrosine kinases. In particular, compounds of this invention are useful as inhibitors of tyrosine kinases that are important in hyperproliferative diseases, especially in cancer and in the process of angiogenesis.

Benzothiazole derivatives

Growing community of inventors

Worcester, MA, United States of America

Kevin Patrick Cusack